AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29576341 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of BMDSCs and their CD133+ fraction
Number of subjects: 0
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein B (Lp-B)
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo-B
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo-C-III-HP
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo-C-III (total)
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-A1:AII
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo-A1
Number of subjects: 417
Study 29576550 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacylglycerols
Number of subjects: 417
Study 29577029 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon Alfa-2a
Number of subjects: 0
Study 29577029 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide Analog
Number of subjects: 0
Study 29577674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 110
Study 29578248 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 1451
Study 29578248 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine dosage
Number of subjects: 1451
Study 29578248 — intervention group
Group type: COMPARATOR
Intervention: Gender, ASA-score, height, weight, BMI, THA vs. TKA
Number of subjects: 1451
Study 29578249 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative serum 25-hydroxyvitamin D concentration
Number of subjects: 123
Study 29578249 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vitamin D deficiency
Number of subjects: 123
Study 29578249 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical control subjects
Number of subjects: 123
Study 29578250 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion 4.8 U/h
Number of subjects: 13
Study 29578250 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion combined with nitroglycerin infusion
Number of subjects: 13
Study 29578250 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 13
Study 29578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 to 100 mg once daily
Number of subjects: 16
Study 29579214 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 1, 2 or 3 g (total of 61 doses)
Number of subjects: 16
Study 29579214 — intervention group
Group type: EXPERIMENTAL
Intervention: New temocillin dosage regimen (not specified in detail)
Number of subjects: 16
Study 29579214 — intervention group
Group type: COMPARATOR
Intervention: Currently licensed dosage regimen
Number of subjects: 16
Study 29579325 — intervention group
Group type: EXPERIMENTAL
Intervention: veliparib plus temozolomide
Number of subjects: 50
Study 29579331 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 39
Study 29579370 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing (CAT) statements during fMRI
Number of subjects: 31
Study 29579370 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing (CAT) statements
Number of subjects: 31
Study 29579370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pain severity
Number of subjects: 31
Study 29579370 — intervention group
Group type: COMPARATOR
Intervention: Neutral (NEU) statements during fMRI
Number of subjects: 31
Study 29579597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise hyperventilation
Number of subjects: 18
Study 29579597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Number of subjects: 18
Study 29579607 — intervention group
Group type: EXPERIMENTAL
Intervention: WAMI Score
Number of subjects: 6986
Study 29579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular endocardial pacing (LVEP)
Number of subjects: 118
Study 29579617 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac resynchronization therapy (CRT)
Number of subjects: 118
Study 29580174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 214
Study 29581087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostom-i alert sensor (wearable biosensor)
Number of subjects: 20
Study 29581089 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Nights, Better Days (BNBD) internet-based program
Number of subjects: 500
Study 29581089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 29581554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing at low HR (40 bpm)
Number of subjects: 27
Study 29581554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing at middle HR (60 bpm)
Number of subjects: 27
Study 29581554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing at high HR (90 bpm)
Number of subjects: 27
Study 29582687 — intervention group
Group type: EXPERIMENTAL
Intervention: LARC
Number of subjects: 6744
Study 29582687 — intervention group
Group type: COMPARATOR
Intervention: Non-LARC hormonal contraceptives
Number of subjects: 6744
Study 29582894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (fish oil)
Number of subjects: 50
Study 29583084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical smears performed by general practitioners (GPs)
Number of subjects: 90094
Study 29583084 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs performing smears
Number of subjects: 90094
Study 29583084 — intervention group
Group type: EXPERIMENTAL
Intervention: Female GPs
Number of subjects: 90094
Study 29584546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity
Number of subjects: 243
Study 29584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 44
Study 29584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean diabetic group
Number of subjects: 6480
Study 29584721 — intervention group
Group type: COMPARATOR
Intervention: Young group
Number of subjects: 6480
Study 29584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly/AF group
Number of subjects: 6480
Study 29584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic group
Number of subjects: 6480
Study 29584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic group
Number of subjects: 6480
Study 29587656 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 385
Study 29587672 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment initiation
Number of subjects: 1402
Study 29587672 — intervention group
Group type: COMPARATOR
Intervention: Switching antidepressants
Number of subjects: 1402
Study 29587677 — intervention group
Group type: EXPERIMENTAL
Intervention: OTS-GC-A24 cancer vaccine at 1 mg administered in 3-weekly (3w), 2-weekly (2w), and weekly (1w) cohorts.
Number of subjects: 24
Study 29587682 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally based weight loss intervention (calorie reduction, exercise, behavior modification) over 6 months
Number of subjects: 0
Study 29587682 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants who lost less than 5% weight)
Number of subjects: 0
Study 29587709 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TOFHLA
Number of subjects: 187
Study 29587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measured with GAD-7 scale
Number of subjects: 106
Study 29587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain intensity
Number of subjects: 106
Study 29587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels assessed on NRS
Number of subjects: 106
Study 29587759 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular pain medication intake
Number of subjects: 106
Study 29587807 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 120
Study 29587807 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Acceptance and Commitment Therapy (ACT)
Number of subjects: 120
Study 29587807 — intervention group
Group type: COMPARATOR
Intervention: Control condition without bias modification
Number of subjects: 120
Study 29587808 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP in combination with 400 mg MTZ + 500 mg AMX, starting at the first SRP session (active phase group)
Number of subjects: 180
Study 29587808 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP in combination with 400 mg MTZ + 500 mg AMX, starting after 3 months of its completion (healing phase group)
Number of subjects: 180
Study 29587808 — intervention group
Group type: COMPARATOR
Intervention: SRP-only (control group)
Number of subjects: 180
Study 29587840 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely diagnosis of PTB
Number of subjects: 359
Study 29587840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of secondary bacterial pneumonia by prophylactic management
Number of subjects: 359
Study 29587840 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of the timing of cART initiation
Number of subjects: 359
Study 29587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) delivered in deep inspiration breath-hold (DIBH)
Number of subjects: 0
Study 29587881 — intervention group
Group type: COMPARATOR
Intervention: Free breathing (FB)
Number of subjects: 0
Study 29588126 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 3600mg/day
Number of subjects: 60
Study 29588126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29588127 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 755
Study 29588127 — intervention group
Group type: COMPARATOR
Intervention: Opioid drugs
Number of subjects: 755
Study 29588271 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention (6-week training program, 3 sessions per week)
Number of subjects: 24
Study 29588271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 24
Study 29588273 — intervention group
Group type: EXPERIMENTAL
Intervention: BENECA mHealth system
Number of subjects: 20
Study 29588286 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of plasma ceramides (16:0, 18:0, 20:0, 22:0)
Number of subjects: 2086
Study 29588286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide 16:0
Number of subjects: 2086
Study 29588304 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose rivaroxaban added to DAPT (ASA + clopidogrel or ASA + ticagrelor)
Number of subjects: 40
Study 29588304 — intervention group
Group type: COMPARATOR
Intervention: DAPT (ASA + clopidogrel or ASA + ticagrelor) without rivaroxaban
Number of subjects: 40
Study 29588972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 502
Study 29588972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 502
Study 29588972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 502
Study 29588972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 29589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21107
Study 29590008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 0
Study 29590008 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice, e.g., docetaxel 75 mg/m2)
Number of subjects: 0
Study 29590047 — intervention group
Group type: EXPERIMENTAL
Intervention: Translocation of a gut pathobiont
Number of subjects: 0
Study 29590047 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29590311 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 0.5 mg/kg/day for 14 days
Number of subjects: 20
Study 29590311 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal levels of primaquine
Number of subjects: 20
Study 29590311 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of primaquine
Number of subjects: 20
Study 29590318 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 107
Study 29590318 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 107
Study 29590318 — intervention group
Group type: EXPERIMENTAL
Intervention: I-FABP
Number of subjects: 107
Study 29590318 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 107
Study 29590325 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathalyzer-based eHealth system monitoring (Addiction Monitoring Index - AMI)
Number of subjects: 30
Study 29590325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol detection threshold (BrAC = 0.025 mg/l, BACSwe = 0.05‰ or US = 0.0053g/dl)
Number of subjects: 30
Study 29590325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution monitoring of sobriety
Number of subjects: 30
Study 29590325 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI-time profiles
Number of subjects: 30
Study 29590325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of ignored tests
Number of subjects: 30
Study 29590335 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-containing regimen
Number of subjects: 30
Study 29590358 — intervention group
Group type: EXPERIMENTAL
Intervention: Afirma Gene Expression Classifier (GEC)
Number of subjects: 149
Study 29590358 — intervention group
Group type: COMPARATOR
Intervention: ThyroSeq v2 next-generation sequencing
Number of subjects: 149
Study 29590401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injections of (S,S)-[11C]O-methylreboxetine ([11C]MRB) during hypoglycemia
Number of subjects: 9
Study 29590547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus Venetoclax
Number of subjects: 24
Study 29592869 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly $60-per-child benefit
Number of subjects: 52000
Study 29592869 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly $30-per-child benefit
Number of subjects: 52000
Study 29592869 — intervention group
Group type: COMPARATOR
Intervention: No benefit
Number of subjects: 52000
Study 29592876 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party fecal microbiota transplantation (FMT) capsules administered no later than 4 weeks after neutrophil engraftment.
Number of subjects: 18
Study 29592876 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party fecal microbiota transplantation (FMT)
Number of subjects: 18
Study 29593024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia via hyperventilation
Number of subjects: 0
Study 29593024 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 0
Study 29593024 — intervention group
Group type: EXPERIMENTAL
Intervention: Death and disability at 14 days
Number of subjects: 0
Study 29593024 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with the full measurement protocol
Number of subjects: 0
Study 29593025 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-stable trajectory
Number of subjects: 6820
Study 29593025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-marked increase trajectory
Number of subjects: 6820
Study 29593025 — intervention group
Group type: COMPARATOR
Intervention: Lean-stable trajectory
Number of subjects: 6820
Study 29593099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilaralisib tablets (400 mg once daily)
Number of subjects: 22
Study 29593604 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Teacher Program
Number of subjects: 0
Study 29594044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib plus doxorubicin
Number of subjects: 11
Study 29594044 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 11
Study 29594201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG) after concurrent chemoradiation (CRT)
Number of subjects: 152
Study 29594201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG)
Number of subjects: 152
Study 29594250 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (DUR) combined with Cetuximab (CTX) and Radiotherapy (RT) (69.9 Gy/2.12 Gy in 33 fractions)
Number of subjects: 0
Study 29594435 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum carotenoids (α-carotene, β-cryptoxanthin, β-carotene, lycopene, lutein/zeaxanthin, total carotenoids)
Number of subjects: 3336
Study 29594435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum RBP4, triglycerides, HOMA-IR, and BMI
Number of subjects: 3336
Study 29594970 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF agents (monotherapy or combination)
Number of subjects: 90
Study 29594970 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients (overall)
Number of subjects: 90
Study 29594970 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 90
Study 29595064 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 29595064 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax followed by the addition of chemotherapy; specific chemotherapy regimen not mentioned.
Number of subjects: 0
Study 29595298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and affective decision-making constructs related to SES
Number of subjects: 2015
Study 29595298 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-screening behavior relation
Number of subjects: 2015
Study 29596029 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 127
Study 29597136 — intervention group
Group type: EXPERIMENTAL
Intervention: IDQ-S Withdrawal Intolerance
Number of subjects: 0
Study 29597136 — intervention group
Group type: EXPERIMENTAL
Intervention: IDQ-S Lack of Cognitive Coping
Number of subjects: 0
Study 29597136 — intervention group
Group type: EXPERIMENTAL
Intervention: IDQ-S scales
Number of subjects: 0
Study 29598824 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated reproductive, maternal, newborn, and child health intervention delivered by community health workers, which includes home-based antenatal care, post-natal care counseling, mobile application surveillance, Community-Based Integrated Management of Newborn and Childhood Illness, group antenatal and postnatal care, and Balanced Counseling Strategy for post-partum contraception.
Number of subjects: 0
Study 29598861 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Deployment Valves (RDV)
Number of subjects: 22062
Study 29598861 — intervention group
Group type: COMPARATOR
Intervention: Conventional Biological Valves (CBV)
Number of subjects: 22062
Study 29598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 102
Study 29598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 102
Study 29598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients (ESRD)
Number of subjects: 102
Study 29598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical treatment (all patients combined)
Number of subjects: 102
Study 29598933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group (D2D time ≤60 min)
Number of subjects: 2761
Study 29598933 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (D2D time >60 min)
Number of subjects: 2761
Study 29599068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic exposure
Number of subjects: 835
Study 29599068 — intervention group
Group type: COMPARATOR
Intervention: No diuretic exposure (Control)
Number of subjects: 835
Study 29599106 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Spot (Web- and mobile-based map)
Number of subjects: 0
Study 29599106 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 29599185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention for COPD management
Number of subjects: 0
Study 29599185 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29599200 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment (specifics not provided)
Number of subjects: 1020
Study 29599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (consolidation treatment)
Number of subjects: 1020
Study 29599296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS)
Number of subjects: 777
Study 29599296 — intervention group
Group type: COMPARATOR
Intervention: No metabolic syndrome (non-MS)
Number of subjects: 777
Study 29599530 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T-cell therapy
Number of subjects: 1
Study 29599966 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant treatment
Number of subjects: 342
Study 29600778 — intervention group
Group type: EXPERIMENTAL
Intervention: AEMM maps (NOGA XP)
Number of subjects: 33
Study 29600778 — intervention group
Group type: COMPARATOR
Intervention: MRI tagging
Number of subjects: 33
Study 29600824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early concomitant vasopressin and norepinephrine
Number of subjects: 82
Study 29600824 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine monotherapy
Number of subjects: 82
Study 29601256 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV booster (1 dose for Group III, 2 doses for Groups VI and VII)
Number of subjects: 129
Study 29601256 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV (2 doses)
Number of subjects: 129
Study 29601256 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Number of subjects: 129
Study 29601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Nonnutritive Sweeteners (NNS)
Number of subjects: 125
Study 29601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharin
Number of subjects: 125
Study 29601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 125
Study 29601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acesulfame potassium
Number of subjects: 125
Study 29601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 125